Tirzepatide (Mounjaro/Zepbound) and Mental Health

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Unlike semaglutide (which activates only GLP-1 receptors), tirzepatide activates both GIP and GLP-1 receptors, potentially offering distinct neuropsychiatric effects due to the additional GIP receptor activation in the brain.

While GLP-1 receptor brain distribution is well-characterized, GIP receptors are also present in the hippocampus, cortex, and olfactory bulb. GIP receptor activation has been linked to enhanced memory formation, neuroprotection, and neurogenesis in animal models. The dual agonism of tirzepatide means it modulates brain function through two incretin pathways rather than one, though the clinical implications of this difference are still being studied.

The SURMOUNT clinical trial program (weight management) and SURPASS program (diabetes) have not specifically focused on psychiatric endpoints but provide safety data. In these trials, tirzepatide showed no signal for increased depression, anxiety, or suicidality compared to placebo. The most common neuropsychiatric side effects were fatigue and headache, which were generally transient. As with semaglutide, the EMA and FDA have been monitoring all GLP-1-class medications for psychiatric signals.

Both medications share GLP-1 receptor agonism and thus similar effects on the brain's reward and mood circuits. Key differences that may matter psychiatrically:

• Greater weight loss with tirzepatide (up to 22.5% in SURMOUNT-1 vs. ~15% with semaglutide) — more dramatic body changes may have larger psychological impact
• Additional GIP receptor activation — potential additional neuroprotective effects but less studied
• Comparable GI side effects — which can affect psychiatric medication absorption
• Similar reports of reduced 'food noise' and altered relationship with food

The significant appetite suppression and dramatic weight loss with tirzepatide raises concerns for patients with eating disorder histories. Specific considerations include:

• Patients with a history of anorexia nervosa may experience reinforcement of restrictive patterns
• Patients with binge eating disorder may benefit from reduced binge frequency, but the underlying psychological drivers are not addressed by medication alone
• Body image disturbance may worsen as rapid body changes outpace psychological adjustment
• Screening for eating disorders should be standard before prescribing tirzepatide for weight management